PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

MLA

Larissa S. Carnevalli, et al. “PI3Kα/δ Inhibition Promotes Anti-Tumor Immunity through Direct Enhancement of Effector CD8+ T-Cell Activity.” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, Dec. 2018, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s40425-018-0457-0.

APA

Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson, & Simon T. Barry. (2018). PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. Journal for ImmunoTherapy of Cancer, 6(1), 1–14. https://doi.org/10.1186/s40425-018-0457-0

Chicago

Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, et al. 2018. “PI3Kα/δ Inhibition Promotes Anti-Tumor Immunity through Direct Enhancement of Effector CD8+ T-Cell Activity.” Journal for ImmunoTherapy of Cancer 6 (1): 1–14. doi:10.1186/s40425-018-0457-0.